EUVIMEDEUVIMED entdecken
Open Access

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1 / 2 , Germline PALB2 , or Homologous Recombination Deficiency Signature

Felipe Batalini iD, Russell W Madison iD, Ethan S Sokol iD, Dexter X Jin iD, Kuei-Ting Chen, Brennan Decker iD, Dean C Pavlick iD, Garrett M Frampton iD, Gerburg M Wulf iD, Judy E Garber iD, Geoffrey Oxnard iD, Alexa B Schrock iD und 1 weitere

JCO Precision Oncology · 2023

DOI: 10.1200/po.23.00091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Felipe Batalini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Homologous Recombination, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Poly ADP-ribose polymerase inhibitors (PARPi) are approved for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (mBC) and germline pathogenic/likely pathogenic variant (hereafter mutation) in the BRCA1/ 2 genes (g BRCA); however, clinical benefit has also been demonstrated in mBC with somatic BRCA1/ 2 mutations (s BRCA) or germline PALB2 mutations (g PALB2). This study aims to describe the genomic landscape of homologous recombination repair (HRR) gene alterations in mBC and assess PARPi treatment outcomes for patients with g BRCA compared with other HRR genes and by status of a novel homologous recombination deficiency signature (HRDsig). METHODS A real-world (RW) clinico-genomic database (CGDB) of comprehensive genomic profiling (CGP) linked to deidentified, electronic health record–derived clinical data was used. CGP was analyzed for HRR genes and HRDsig. The CGDB enabled cohort characterization and outcomes analyses of 177 patients exposed to PARPi. RW progression-free survival (rwPFS) and RW overall survival (rwOS) were compared. RESULTS Of 28,920 patients with mBC, g BRCA was detected in 3.4%, whereas the population with any BRCA alteration or g PALB2 increased to 9.5%. HRDsig+ represented 21% of patients with mBC. BRCA and g PALB2 had higher levels of biallelic loss and HRDsig+ than other HRR alterations. Outcomes on PARPi were assessed for 177 patients, and g BRCA and s BRCA/ gPALB2 cohorts were similar: g BRCA versus s BRCA/g PALB2 rwPFS was 6.3 versus 5.4 months (hazard ratio [HR], 1.37 [0.77-2.43]); rwOS was 16.2 versus 21.2 months (HR, 1.45 [0.74-2.86]). Additionally, patients with HRDsig+ versus HRDsig– had longer rwPFS (6.3 v 2.8 months; HR, 0.62 [0.42-0.92]) and numerically longer rwOS (17.8 v 13.0 months; HR, 0.72 [0.46-1.14]). CONCLUSION Patients with s BRCA and g PALB2 derive similar benefit from PARPi as those with g BRCA alterations. In combination, HRDsig+, s BRCA, and g PALB2 represent an additional 19% of mBC that can potentially benefit from PARPi. Randomized trials exploring a more inclusive biomarker such as HRDsig are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Homologous RecombinationBreast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsHumansFemaleGenes, BRCA1Genes, BRCA2Fanconi Anemia Complementation Group N ProteinGerm-Line MutationAdultMiddle AgedAged

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsFanconi Anemia Complementation Group N Protein

Autor:innen und Institutionen

  • Mayo Clinic, Phoenix, AZ.
  • Foundation Medicine, Inc, Boston, MA.
  • Beth Israel Deaconess Medical Center, Boston, MA.
  • Dana Farber Cancer Institute, Boston, MA.

ORCID-Profile: Felipe Batalini, Russell W Madison, Ethan S Sokol, Dexter X Jin, Brennan Decker, Dean C Pavlick, Garrett M Frampton, Gerburg M Wulf, Judy E Garber, Geoffrey Oxnard, Alexa B Schrock, Nadine M Tung

Zitieren

APA

Batalini, F., Madison, R. W., Sokol, E. S., Jin, D. X., Chen, K. T., Decker, B., Pavlick, D. C., Frampton, G. M., Wulf, G. M., Garber, J. E., Oxnard, G., Schrock, A. B., & Tung, N. M. (2023). Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1 / 2 , Germline PALB2 , or Homologous Recombination Deficiency Signature. JCO Precision Oncology. https://doi.org/10.1200/po.23.00091

Vancouver

Batalini F, Madison RW, Sokol ES, Jin DX, Chen KT, Decker B, et al. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1 / 2 , Germline PALB2 , or Homologous Recombination Deficiency Signature. JCO Precision Oncology. 2023. doi:10.1200/po.23.00091

BibTeX
@article{Batalini2023,
  author = {Batalini, Felipe and Madison, Russell W and Sokol, Ethan S and Jin, Dexter X and Chen, Kuei-Ting and Decker, Brennan and Pavlick, Dean C and Frampton, Garrett M and Wulf, Gerburg M and Garber, Judy E and Oxnard, Geoffrey and Schrock, Alexa B and Tung, Nadine M},
  title = {Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1 / 2 , Germline PALB2 , or Homologous Recombination Deficiency Signature},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.23.00091}
}
Kostenlos starten →